JP2017527576A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527576A5
JP2017527576A5 JP2017513205A JP2017513205A JP2017527576A5 JP 2017527576 A5 JP2017527576 A5 JP 2017527576A5 JP 2017513205 A JP2017513205 A JP 2017513205A JP 2017513205 A JP2017513205 A JP 2017513205A JP 2017527576 A5 JP2017527576 A5 JP 2017527576A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
lymphoma
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049217 external-priority patent/WO2016040502A1/en
Publication of JP2017527576A publication Critical patent/JP2017527576A/ja
Publication of JP2017527576A5 publication Critical patent/JP2017527576A5/ja
Pending legal-status Critical Current

Links

JP2017513205A 2014-09-10 2015-09-09 置換シクロヘキシルアミン化合物 Pending JP2017527576A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048756P 2014-09-10 2014-09-10
US62/048,756 2014-09-10
PCT/US2015/049217 WO2016040502A1 (en) 2014-09-10 2015-09-09 Substituted cyclohexylamine compounds

Publications (2)

Publication Number Publication Date
JP2017527576A JP2017527576A (ja) 2017-09-21
JP2017527576A5 true JP2017527576A5 (enExample) 2018-10-18

Family

ID=55459525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513205A Pending JP2017527576A (ja) 2014-09-10 2015-09-09 置換シクロヘキシルアミン化合物

Country Status (6)

Country Link
US (1) US10106510B2 (enExample)
EP (1) EP3190891B1 (enExample)
JP (1) JP2017527576A (enExample)
AU (1) AU2015315171A1 (enExample)
CA (1) CA2960271A1 (enExample)
WO (1) WO2016040502A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526706A (ja) 2014-09-10 2017-09-14 エピザイム,インコーポレイティド イソオキサゾールカルボキサミド化合物
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
JP2017528460A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド
AU2024258350A1 (en) * 2023-04-19 2025-10-30 Alcon Inc. N-substituted c6 cyclyl carboxamide compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089398A1 (en) * 2003-03-19 2006-04-27 Gang Liu Isoxazole carboxamide derivatives as ghrelin receptor modulators
GB0317484D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
CA2721065C (en) * 2008-05-27 2016-09-27 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use as pde4 inhibitors
SI2310356T1 (sl) * 2008-07-25 2014-02-28 H. Lundbeck A/S Adamantil diamid derivati in uporaba le-teh
JP6135391B2 (ja) 2013-08-16 2017-05-31 ソニー株式会社 撮像装置、画像処理装置、および画像処理方法、並びにプログラム
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
JP2017528460A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド
JP2017526706A (ja) 2014-09-10 2017-09-14 エピザイム,インコーポレイティド イソオキサゾールカルボキサミド化合物
US20170247326A1 (en) 2014-09-10 2017-08-31 Epizyme, Inc. Substituted Pyrrolidine Carboxamide Compounds
US20170253601A1 (en) 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds

Similar Documents

Publication Publication Date Title
JP2017527576A5 (enExample)
JP2017527577A5 (enExample)
JP2017528464A5 (enExample)
JP2016514695A5 (enExample)
JP2017528460A5 (enExample)
JP2017526706A5 (enExample)
JP2019514950A5 (enExample)
JP2017538659A5 (enExample)
MA40581A (fr) Dérivés pyridone utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
JP2019509354A5 (enExample)
WO2007053573A2 (en) Treatment of cancer with sorafenib
JP2020515571A5 (enExample)
CN104039798A (zh) 具有蛋白激酶抑制活性的噻吩并[3,2-d]嘧啶衍生物
WO2008089388A3 (en) Treatment of cancers having resistance to chemotherapeutic agents
JP2017537946A5 (enExample)
JP2009536156A5 (enExample)
EP2193211A4 (en) IDENTIFICATION OF NEW WAYS FOR ACTIVE DEVELOPMENT FOR LUNG DRESS
JP2019504830A5 (enExample)
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
EP2844256A4 (en) TREATMENT OF NEURONAL DISEASES WITH TYROSINE CHINESE INHIBITORS
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
Sunil et al. Oxazepine derivative as an antitumor agent and snail1 inhibitor against human colorectal adenocarcinoma
CN101959533A (zh) 嘧啶衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的物质具有获得性耐药性的疾病中的用途
WO2020128475A1 (en) Cancer treatments
EP3030550A1 (en) Styryl quinazoline derivatives as pharmaceutically active agents